End points
death
DISEASE PROGRESSION, SECONDARY, ADVERSE EVENT, ADVERSE EVENT
The primary endpoint was the objective response rate (ORR), which was defined as the percentage of patients who achieved CR and PR after receiving treatment. The secondary endpoint was progression‐free survival (PFS), as defined as the period from the first day of treatment with toripalimab and anlotinib to discontinuation due to disease progression or intolerance to treatment. PFS2 was defined as the period from treatment after withdrawal from the group until disease progression occurred again. The overall survival (OS) was the time from the start of enrollment treatment to death or the last follow‐up. Adverse events in this study were measured on the basis of the Common Terminology Criteria for Adverse Events (CTCAE 5.0). Follow‐up continued until the last patient was out of group for 3 months.